Compare Medpace Holdings Inc (MEDP) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Tenet Healthcare Corporation — how do they compare? Medpace Holdings Inc trades at $616.5 (market cap $16.82B), while Tenet Healthcare Corporation trades at $262.4 (market cap $20.98B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Tenet Healthcare Corporation is more actively traded (428,008 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Tenet Healthcare Corporation for 15 Days on average.
| MEDP | THC | |
|---|---|---|
Market Cap | $16.82B | $20.98B |
Volume | 223,093 | 428,008 |
Sector | Health | Health |
52-Week High | $630.19 | $280.77 |
52-Week Low | $393.42 | $161.37 |
Typical Hold Time | 14 Days | 15 Days |
Enterprise Value | $16.44B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Tenet Healthcare (THC) trades at $261.07, up 0.48% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 82.83% gross margins and consistent earnings beats, while trading at attractive valuations including a 10.07 P/E ratio. Recent news highlights upcoming Q3 2026 earnings on October 29th and positive coverage of the company's growth prospects despite surgical volume challenges.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $283.36 consensus target offering 8.5% upside. The healthcare provider shows improving profitability with net margins expected to reach 9.89% in 2026. Key risks include capital allocation sustainability and potential volatility around upcoming earnings, but the combination of value pricing and growth momentum supports a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
